FY2026 results: Revenue 31,105 million yen (YoY +4.0%), Operating Income 2,625 million yen (YoY -10.9%), etc. FY2026 results were largely in line with plans, but Net Income declined year-on-year. FY2027 outlook: Revenue 33,000 million yen, Operating Income 2,800 million yen. Mid- to long-term growth drivers include Pharmacy DX and School DX. Dividend policy is also indicated as part of capital policy.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9438","jir_company_name":"MTI Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/9438-20261111-01.pdf","jir_short_summary":"FY2026 results: Revenue 31,105 million yen (YoY +4.0%), Operating Income 2,625 million yen (YoY -10.9%), etc. FY2026 results were largely in line with plans, but Net Income declined year-on-year. FY2027 outlook: Revenue 33,000 million yen, Operating Income 2,800 million yen. Mid- to long-term growth drivers include Pharmacy DX and School DX. Dividend policy is also indicated as part of capital policy.","jir_summary":"### Summary of Performance\nFY2026 revenue increased to 31,105 million yen (YoY +4.0%). However, operating income declined to 2,625 million yen and net income decreased to 2,224 million yen. By segment, Healthcare and School DX showed growth, while increased expenses pushed up selling, general and administrative expenses. For the next fiscal year, we forecast revenue of 33,000 million yen and operating income of 2,800 million yen.\n\n### Financial Position and Outlook\nFY2026 results were generally in line with plan, but net income was adversely affected by factors such as software impairment. For FY2027, we expect revenue growth while focusing on controlling selling, general and administrative expenses and expanding growth segments. Initiatives in Pharmacy DX, Childcare DX and School DX will be strengthened as medium- to long-term growth engines.","jir_financial_highlights":"Revenue: 31,105 million yen (YoY +4.0%)\nOperating Income: 2,625 million yen (YoY -10.9%)\nNet Income Attributable to Owners of Parent: 2,224 million yen (YoY -34.6%)\nRevenue (FY2026 Latest Forecast vs Actual Difference): 31,500 vs 31,105 (Difference -394)","jir_category":"","jir_hashtags":"#MTILtd, #Earnings, #MidTermPlan, #SchoolDX, #PharmacyDX","jir_key_figures":"Revenue: 31,105 million yen (YoY +4.0%)\nOperating Income: 2,625 million yen (YoY -10.9%)\nNet Income Attributable to Owners of Parent: 2,224 million yen (YoY -34.6%)","jir_meta_title":"MTI Ltd. FY2026 Earnings Overview | Revenue 31,105 million yen (+4.0%) \u00b7 Operating Income 2,625 million yen","jir_meta_description":"MTI Ltd. FY2026 earnings overview. Revenue 31,105 million yen, Operating Income 2,625 million yen, Net Income 2,224 million yen. FY2027 outlook assumes revenue 33,000 million yen and operating income 2,800 million yen. Explanation of segment growth initiatives and cost factors.","jir_og_title":"MTI Ltd. FY2026 Earnings Overview | Growth Strategy and Next Year Outlook","jir_og_description":"Key points of FY2026 results, FY2027 outlook, segment performance, cost factors, and dividend policy summarized.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[31250,31105]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[? , 2625]}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"School DX\\\",\\\"Healthcare\\\",\\\"Contents\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[? , ?, ?, ?]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Margin\\\",\\\"data\\\":[9.8, 8.4]}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Guidance vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026\\\",\\\"FY2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[31105, 33000]},{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[2625, 2800]}]}}\"}]","ir_related_company":17570,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-148286","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n